SBC Medical Group Holdings (SBC) Q3 2026 earnings summary

Executive summary

• 3Q26 revenue rose 35.13% YoY to $58.6M; operating income increased 66.34% to $26.4M, attributable net income rose 22.36% to $15.7M, and Adjusted EBITDA grew 66% to $27.6M.

• Growth reflected management services, August service-fee revisions, clinic openings and Waqoo consolidation; yen depreciation weighed on reported results.

Financial highlights

• 9M26 revenue was $150.8M, up 12.53%; operating income was $63.1M, up 15.48%, and attributable net income was $37.7M, up 2.47%.

• Adjusted EBITDA was $66.1M for 9M26, up 17%; basic EPS was $0.15 for Q3 and $0.37 for 9M.

• 9M26 operating cash flow was $50.2M, versus $27.3M used in 9M25.

Outlook and guidance

• Medium- to long-term priorities include sustained EPS growth, disciplined investment, and improved clinic productivity and profitability.

• Plans include expanding aesthetic and non-aesthetic services in Japan, collaboration with OrangeTwist in the U.S., and growth in ASEAN markets.

• Longevity plans include biological-age testing, a longevity center and online platform in 2027, followed by AI-supported personalized protocols and international menu rollout in 2027–28.

• Six proprietary local-LLM features are in development for clinical documentation, scheduling, security, marketing and treatment/customer recommendations.